// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1321 Abstracts

Liquid biopsy in the clinic: A prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy.

Joshua K. Sabari - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients.

Shun Lu - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach.

Shumei Kato - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).

Derek L. Clouthier - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Association of early reduction in circulating tumor DNA (ctDNA) with improved progression-free survival (PFS) and overall survival (OS) of patients (pts) with urothelial bladder cancer (UBC) treated with durvalumab (D).

Michael Kuziora - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Durvalumab

Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Frederic Bigot - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).

Jeanne Tie - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.

Michael J. Overman - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA analysis using targeted sequencing of 508 clinically actionable genes in patients with high grade serous ovarian cancer.

Anniina Farkkila - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Carboplatin

Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Yada Kanjanapan - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Olaparib

Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).

Jenny HJ Lee - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA as a predictor for response to treatment in BRAF V600E mutant malignant melanoma.

Jan Braune - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Monitoring the effect of first-line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.

Caroline Brenner Thomsen - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

Jayesh Desai - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Vemurafenib

Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).

Maximilian Diehn - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA analysis before and after resection for colorectal cancer.

Erin L. Symonds - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.

Tej D. Azad - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.

Belinda Lee - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA).

Nathan Bahary - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis.

Ben-Yuan Jiang - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved